论文部分内容阅读
Background:Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening clinical syndrome.Central nervous system (CNS) involvement is a severe complication,which can lead to rapid disease development and higher morality.However,this has not been given enough attention in adult HLH.Therefore,we carried out this study to analyze the clinical features,laboratory findings,treatment outcomes,and other characteristics of adult HLH with CNS involvement.Methods:A retrospective analysis of 96 adult patients with HLH combined with CNS involvement between June 2003 and December 2016 was conducted.Clinical features,cerebrospinal fluid (CSF) features,image changes,and therapeutic outcomes were analyzed.Results:Among the 96 patients,86 had various CNS symptoms and 33 (38.4％) had already presented symptoms before the HLH diagnosis was confirmed.A total of 59 patients received CSF examinations and showed abnormalities in 23 patients (39.0％).Seventy patients received imaging examinations and the results showed fifty patients with imaging changes (71.4％).Fifty-seven patients received multiple rounds of repeated intrathecal injection therapy and 35 patients improved (61.4％).As for the multiple analyses of effective factors on survival time,the results showed that the effects of combined Epstein-Barr virus (EBV) infection (P =0.026,Exp(B) =2.309,95％ confidence interval [CI] [1.108,4.823) and intrathecal injection therapy (P =0.013,Exp(B) =0.422,95％ CI [0.214,0.831]) on the survival time of the CNS-HLH patients were significant.Conclusions:Complication with EBV infection is a risk factor,and intrathecal injection is a protective factor.CNS involvement in HLH is not rare,which can result in a poor prognosis.Multiple rounds of repeated intrathecal injection therapy can improve the prognosis of CNS-HLH patients.